Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Salvianolic Acid B prevents arsenic trioxide-induced cardiotoxicity in vivo and enhances its anticancer activity in vitro.

Wang M, Sun G, Wu P, Chen R, Yao F, Qin M, Luo Y, Sun H, Zhang Q, Dong X, Sun X.

Evid Based Complement Alternat Med. 2013;2013:759483. doi: 10.1155/2013/759483. Epub 2013 Apr 8.

2.

Cardioprotective effect of salvianolic acid B against arsenic trioxide-induced injury in cardiac H9c2 cells via the PI3K/Akt signal pathway.

Wang M, Sun GB, Sun X, Wang HW, Meng XB, Qin M, Sun J, Luo Y, Sun XB.

Toxicol Lett. 2013 Feb 4;216(2-3):100-7. doi: 10.1016/j.toxlet.2012.11.023. Epub 2012 Nov 30.

PMID:
23201927
3.

[Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research].

Zhou XJ, Zhou YH, Chen XH, Qian WB.

Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Jun;33(6):834-9. Chinese.

PMID:
23980369
4.
5.

Synergistic inhibition of leukemia WEHI-3 cell growth by arsenic trioxide and Hedyotis diffusa Willd extract in vitro and in vivo.

Kuo YJ, Liu YJ, Way TD, Chiang SY, Lin JG, Chung JG.

Exp Ther Med. 2017 Jun;13(6):3388-3396. doi: 10.3892/etm.2017.4392. Epub 2017 Apr 27.

7.
8.

Tumour growth-suppressive effect of arsenic trioxide in squamous cell lung carcinoma.

Leung LL, Lam SK, Li YY, Ho JC.

Oncol Lett. 2017 Sep;14(3):3748-3754. doi: 10.3892/ol.2017.6646. Epub 2017 Jul 21.

PMID:
28927142
9.

Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo.

Xu Y, Liu Z, Sun J, Pan Q, Sun F, Yan Z, Hu X.

PLoS One. 2011;6(12):e28335. doi: 10.1371/journal.pone.0028335. Epub 2011 Dec 2. Erratum in: PLoS One. 2012;7(1). doi:10.1371/annotation/7a1b01e4-b894-40ef-9c31-584e9c24ee0a.

10.

Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation.

Nakamura S, Nagano S, Nagao H, Ishidou Y, Yokouchi M, Abematsu M, Yamamoto T, Komiya S, Setoguchi T.

PLoS One. 2013 Jul 8;8(7):e69466. doi: 10.1371/journal.pone.0069466. Print 2013.

11.

Evaluation of Arsenic Trioxide Potential for Lung Cancer Treatment: Assessment of Apoptotic Mechanisms and Oxidative Damage.

Walker AM, Stevens JJ, Ndebele K, Tchounwou PB.

J Cancer Sci Ther. 2016 Jan;8(1):1-9. Epub 2015 Dec 18.

12.

Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide.

Chien CW, Yao JH, Chang SY, Lee PC, Lee TC.

Toxicol Appl Pharmacol. 2011 Nov 15;257(1):59-66. doi: 10.1016/j.taap.2011.08.018. Epub 2011 Aug 25.

PMID:
21889949
13.

Arsenic trioxide prevents radiation-enhanced tumor invasiveness and inhibits matrix metalloproteinase-9 through downregulation of nuclear factor kappaB.

Wei LH, Lai KP, Chen CA, Cheng CH, Huang YJ, Chou CH, Kuo ML, Hsieh CY.

Oncogene. 2005 Jan 13;24(3):390-8.

PMID:
15531921
14.

Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma.

Jiang H, Ma Y, Chen X, Pan S, Sun B, Krissansen GW, Sun X.

Cancer Sci. 2010 Apr;101(4):975-83. doi: 10.1111/j.1349-7006.2009.01464.x. Epub 2009 Dec 9. Erratum in: Cancer Sci. 2010 Jun;101(6):1574.

15.

PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.

Luo Q, Li Y, Deng J, Zhang Z.

Chem Biol Interact. 2015 Jan 25;226:12-22. doi: 10.1016/j.cbi.2014.12.007. Epub 2014 Dec 11.

PMID:
25499136
16.

Combination of arsenic trioxide and chemotherapy in small cell lung cancer.

Zheng CY, Lam SK, Li YY, Fong BM, Mak JC, Ho JC.

Lung Cancer. 2013 Nov;82(2):222-30. doi: 10.1016/j.lungcan.2013.08.022. Epub 2013 Sep 3.

PMID:
24041618
17.

Arsenic trioxide inhibits CXCR4-mediated metastasis by interfering miR-520h/PP2A/NF-κB signaling in cervical cancer.

Chang YW, Chen MW, Chiu CF, Hong CC, Cheng CC, Hsiao M, Chen CA, Wei LH, Su JL.

Ann Surg Oncol. 2014 Dec;21 Suppl 4:S687-95. doi: 10.1245/s10434-014-3812-5. Epub 2014 Jul 22.

PMID:
25047463
18.

Downregulation of thymidylate synthase and E2F1 by arsenic trioxide in mesothelioma.

Lam SK, Li YY, Zheng CY, Ho JC.

Int J Oncol. 2015 Jan;46(1):113-22. doi: 10.3892/ijo.2014.2716. Epub 2014 Oct 21.

PMID:
25335113
19.

Shikonin potentiates the effect of arsenic trioxide against human hepatocellular carcinoma in vitro and in vivo.

Song J, Zhao Z, Fan X, Chen M, Cheng X, Zhang D, Wu F, Ying X, Ji J.

Oncotarget. 2016 Oct 25;7(43):70504-70515. doi: 10.18632/oncotarget.12041.

20.

Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma.

Lam SK, Leung LL, Li YY, Zheng CY, Ho JC.

Lung Cancer. 2016 Nov;101:111-119. doi: 10.1016/j.lungcan.2016.10.001. Epub 2016 Oct 4.

PMID:
27794399

Supplemental Content

Support Center